MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2017 International Congress

    Serum cholesterol levels over time and risk of Parkinson’s disease

    V. Rozani, T. Gurevich, N. Giladi, B. El-Ad, J. Tsamir, B. Hemo, C. Peretz (Tel A viv, Israel)

    Objective: To evaluate the association of serum cholesterol levels over time with the risk of Parkinson's disease (PD); among statin-free individuals. Background: High levels of…
  • 2017 International Congress

    Variation in Longevity Gene KLOTHO Associates with Measures of Resilience Against Parkinson’s Disease

    N. Luthra, J. Ostrem, D. Dubal (San Francisco, CA, USA)

    Objective: We investigated whether carrying one copy of the protective haplotype “KL-VS” of the longevity gene KLOTHO is associated with better cognitive functioning and/or attenuated…
  • 2017 International Congress

    Neuroactive steroids reverse the dopaminergic neurotransmission defectiveness in chronic hepatic (HE) encephalopathy: a possible involvement in HE related parkinsonism

    O. El Hiba, A. EL Khiat, H. Gamrani (EL Jadida, Morocco)

    Objective: In the present study, we describe the changes of the dopaminergic system occurring in the cirrhotic rats and concomitantly we investigated the effect of…
  • 2017 International Congress

    Relationship between Insulin-like Growth Factor-1 and characteristics of physical activity in patients with Parkinson’s disease

    K. Nagaki, M. Ikenaga, S. Fujioka, Y. Tsuboi (fukuoka, Japan)

    Objective: To clarify the characteristics of decreased physical activity and relationship between physical activity intensity and Insulin-like Growth Factor-1 (IGF-1) in patients with Parkinson's disease…
  • 2017 International Congress

    Deep Brain Stimulation for Parkinson Disease before L-dopa treatment: experience in three cases.

    d. servello, M. Porta, e. zekaj (Milano, Italy)

    Objective:   The goal of these case series is to investigate the possibility of deep brain stimulation (DBS) prior to L-dopa treatment in young Parkinsson…
  • 2017 International Congress

    Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease

    G. Pagano, T. Yousaf,, C. Loane, S. Polychronis, H. Wilson, B. Giordano, F. Niccolini, M. Politis (London, United Kingdom)

    Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • 2017 International Congress

    The therapeutic effect of MANF in the MPTP/MPP+-induced model of Parkinson’s disease

    y. liu (shanghai city, China)

    Objective: To observe therapeutic effect of MANF in the attenuation of neurotoxin MPTP/MPP+-induced model of Parkinson's disease Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a…
  • 2017 International Congress

    Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat

    R. Bansal, R. Singh (Chandigarh, India)

    Objective: The present study is aimed at design and synthesis of new therapeutically useful steroidal neuroprotective derivatives as anti-parkinsonian agents. The new 16-aryldieno steroidal derivatives…
  • 2017 International Congress

    Cinnamomum verum on Learning and Memory in Wistar Albino Rats

    N. AHMED, D. AGRAWAL, A. CHUGHTAI (ALIGARH, India)

    Objective: Several studies have been performed on Cinnamomum verum,but not much is known about the activity of Cinnamomum verum on Memory Enhancing.Therefore Cinnamomum verum is selected…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley